EAY191-S3 Advanced non-breast solid tumors with AKT-alterations

What is the Purpose of this Study?

We are doing this study to find out if combining a drug called ipatasertib with the chemotherapy drug paclitaxel can help shrink or control solid tumors that have AKT gene mutations.

What is the Condition Being Studied?

Advance Solid Tumors with AKT Gene Mutations

Who Can Participate in the Study?

Adults ages 18+ who:

  • Are enrolled in the ComboMATCH Registration Protocol (EAY191)
  • Have have locally advanced, unresectable, or metastatic malignancy
  • Have an activating AKT gene mutation (AKT1, AKT2, or AKT3)
  • Do not have an activating KRAS, NRAS, HRAS, or BRAF mutation

For more information about who can join this study, please contact the study team at nick.jeffries@duke.edu.

Age Group

What is Involved?

If you choose to join this study, you will take ipatasertib by mouth days 1-21 of each drug cycle. You will also receive paclitaxel through a vein in your arm (IV) on days 1, 8, and 15 of each drug cycle. Each cycle lasts for 28 days. The number of cycles you do in this study will depend on how you respond to the study drug regimen.

Study Details

Full Title
EAY191-S3: Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial
Principal Investigator
Associate Professor of Medicine
Protocol Number
IRB: PRO00114179
NCT: NCT05554380
Phase II
Enrollment Status